Pular para o conteúdo
Adenocarcinoma do esôfago
ORPHA:99976CID-10 · C15.2CID-11 · 2B70.0DOENÇA RARA
Esta doença tem causa genética. Recomendamos procurar um médico geneticista para diagnóstico, exames genéticos e aconselhamento familiar.
Início adultaHerança Unknown
Sinônimos clínicos: Adenocarcinoma esofágico

Tumor maligno com diferenciação glandular originando-se predominantemente da mucosa de Barrett no terço inferior do esôfago. Exemplos raros de adenocarcinoma esofágico derivado de mucosa gástrica ectópica na parte superior do esôfago também foram relatados. Grosso modo, os adenocarcinomas esofágicos são semelhantes aos carcinomas espinocelulares esofágicos. Microscopicamente, os adenocarcinomas que surgem no contexto do esôfago de Barrett são tipicamente papilares e/ou tubulares. O prognóstico é ruim.

Última verificação: Fonte: sem afirmação sobre o SUS a verificarEm construçãohistóricoSugerir correção
Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

💬
EM LINGUAGEM SIMPLES

O **adenocarcinoma do esôfago** é um tumor maligno que afeta principalmente a parte inferior do esôfago, frequentemente ligado ao histórico de refluxo e alterações na mucosa. As pessoas afetadas costumam sentir desconforto no peito, tosse, náuseas e vômitos decorrentes da evolução do tumor. Na rede pública do Brasil, o atendimento ocorre no âmbito do protocolo de carcinoma de esôfago, sendo as condutas definidas conforme a autonomia técnica de cada serviço credenciado. Novas abordagens e medicamentos estão sob constante investigação científica em ensaios clínicos abertos no mundo e no país.

📋
Informacoes curadas por IA — podem conter imprecisoes

Tumor maligno com diferenciação glandular originando-se predominantemente da mucosa de Barrett no terço inferior do esôfago. Exemplos raros de adenocarcinoma esofágico derivado de mucosa gástrica ectópica na parte superior do esôfago também foram relatados. Grosso modo, os adenocarcinomas esofágicos são semelhantes aos carcinomas espinocelulares esofágicos. Microscopicamente, os adenocarcinomas que surgem no contexto do esôfago de Barrett são tipicamente papilares e/ou tubulares. O prognóstico é ruim.

Pesquisas ativas
107 ensaios
361 total registrados no ClinicalTrials.gov
Medicamentos
9 com registro
DOCETAXEL, TACE, TEQUEL

Tem tratamento?

✓ 9 medicamentos específicos desta doença (registro ANVISA, FDA ou SUS/CEAF)
DOCETAXELTACETEQUELTAXOTERETAXONTASDOCETAXEL (DOCETAXEL ANHYDROUS)MITOMYCIN (MITOMYCIN)CYCLOPHOSPHAMIDE (CYCLOPHOSPHAMIDE)

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-9 / 100 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Europe
Início
Adult
+ elderly
🏥
SUS: Cobertura mínimaScore: 0%
CID-10: C15.2
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🫃
Digestivo
4 sintomas
📏
Crescimento
2 sintomas
🩸
Sangue
1 sintomas
🦴
Ossos e articulações
1 sintomas
🫁
Pulmão
1 sintomas

+ 1 sintomas em outras categorias

Características mais comuns

90%prev.
Refluxo gastroesofágico
Muito frequente (99-80%)
90%prev.
Obesidade
Muito frequente (99-80%)
90%prev.
Clinodactilia do quinto pododáctilo
Muito frequente (99-80%)
90%prev.
Dificuldades alimentares na infância
Muito frequente (99-80%)
90%prev.
Carcinoma esofágico
Muito frequente (99-80%)
90%prev.
Esôfago de Barrett
Muito frequente (99-80%)
10sintomas
Muito frequente (6)
Frequente (3)
Ocasional (1)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 10 características clínicas mais associadas, ordenadas por frequência.

Refluxo gastroesofágicoGastroesophageal reflux
Muito frequente (99-80%)90%
ObesidadeObesity
Muito frequente (99-80%)90%
Clinodactilia do quinto pododáctiloClinodactyly of the 5th toe
Muito frequente (99-80%)90%
Dificuldades alimentares na infânciaFeeding difficulties in infancy
Muito frequente (99-80%)90%
Carcinoma esofágicoEsophageal carcinoma
Muito frequente (99-80%)90%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa4
Últimos 10 anos200publicações
Pico202366 papers
Linha do tempo
2022Hoje · 2026🧪 1995Primeiro ensaio clínico📈 2023Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

1 gene identificado com associação a esta condição. Padrão de herança: Not applicable.

ERBB2Receptor tyrosine-protein kinase erbB-2Biomarker tested inRestrito
VIAS BIOLÓGICAS (9)
Signaling by ERBB2Constitutive Signaling by Overexpressed ERBB2Drug-mediated inhibition of ERBB2 signalingDownregulation of ERBB2 signalingSema4D induced cell migration and growth-cone collapse
MECANISMO DE DOENÇA

Glioma

Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
130.1 TPM
Skin Sun Exposed Lower leg
118.3 TPM
Esôfago - Mucosa
113.1 TPM
Skin Not Sun Exposed Suprapubic
110.9 TPM
Tireoide
99.3 TPM
OUTRAS DOENÇAS (9)
gastric cancervisceral neuropathy, familial, 2, autosomal recessiveglioma susceptibility 1lung cancer
HGNC:3430UniProt:P04626

Medicamentos aprovados (FDA)

4 medicamentos encontrados nos registros da FDA americana.

💊 Docetaxel (DOCETAXEL ANHYDROUS)
💊 Mitomycin (MITOMYCIN)
💊 CYCLOPHOSPHAMIDE (CYCLOPHOSPHAMIDE)
💊 Gemcitabine (GEMCITABINE HYDROCHLORIDE)
Ver no DailyMed/FDA

Variantes genéticas (ClinVar)

58 variantes patogênicas registradas no ClinVar.

🧬 ERBB2: GRCh37/hg19 17q12-21.2(chr17:33220181-39572233)x3 ()
🧬 ERBB2: NM_004448.4(ERBB2):c.2264T>G (p.Leu755Trp) ()
🧬 ERBB2: NM_004448.4(ERBB2):c.643+48G>A ()
🧬 ERBB2: GRCh37/hg19 17q12-22(chr17:41196270-41277589) ()
🧬 ERBB2: NM_004448.4(ERBB2):c.1460G>A (p.Arg487Gln) ()
Ver todas no ClinVar

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Adenocarcinoma do esôfago

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Onde estão os ensaios

Com ensaio aberto em 36 países. O ponto verde marca onde há vaga agora.

🟢 Recrutando agora

72 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

NCT07221149 · A Study to Evaluate the Safety and Efficacy of Pumitamig in …Recrutando
PHASE2, PHASE3🇧🇷 Brasil · 🇦🇷 Argentina · 🇦🇺 Austrália +17
NCT07431281 · Sonesitatug Vedotin in Combination With Capecitabine With or…Recrutando
PHASE3🇧🇷 Brasil · 🇦🇺 Austrália · 🇦🇹 Áustria +21
NCT06330064 · A Study to Evaluate the Efficacy and Safety of Ifinatamab De…Recrutando
PHASE1, PHASE2🇧🇷 Brasil · 🇦🇷 Argentina · 🇦🇺 Austrália +15
NCT07594548 · Futibatinib With Paclitaxel and Ramucirumab for the Treatmen…Recrutando
PHASE1🇺🇸 Estados Unidos
NCT07603375 · Upfront Chemotherapy With Radiation Therapy (CRT) Followed b…Recrutando
PHASE2🇺🇸 Estados Unidos
NCT07439484 · Individually Tailored, Supervised, Remote Exercise Intervent…Recrutando
NA🇺🇸 Estados Unidos
NCT07818018 · A Study of 2141-V11 in People With Esophageal, Gastric, or G…Recrutando
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT07714538 · Breath Research Narrow Validation for Gastrointestinal Cance…Recrutando
🇬🇧 Reino Unido
NCT06732388 · Itraconazole in Combination With Ablation for the Prevention…Recrutando
PHASE2🇺🇸 Estados Unidos
NCT07222657 · Liquid Nitrogen Spray Cryotherapy Prior to Neoadjuvant Syste…Recrutando
PHASE2🇺🇸 Estados Unidos
NCT07282912 · Trial Comparing Standard of Care Therapy With and Without Se…Recrutando
PHASE2🇺🇸 Estados Unidos
NCT06824363 · ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gas…Recrutando
EARLY_PHASE1🇺🇸 Estados Unidos
NCT07392892 · Symbiotic-GI-16: A Study to Learn About the Study Medicine C…Recrutando
PHASE2, PHASE3🇨🇦 Canadá · 🇨🇳 China · 🇫🇷 França +7
NCT07544589 · A Phase 1 Study Evaluating DISP-10 in Participants With Adva…Recrutando
PHASE1🇺🇸 Estados Unidos
NCT07343869 · Multicenter Prospective Cohort on Esophageal Endoscopic Subm…Recrutando
🇫🇷 França
NCT07622940 · Dual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophage…Recrutando
PHASE1, PHASE2🇨🇳 China
NCT07432295 · Givastomig Combined With Nivolumab and Chemotherapy in Adult…Recrutando
PHASE2🇨🇳 China · 🇯🇵 Japão · 🇺🇸 Estados Unidos
NCT07059299 · A Phase Ib Trial Evaluating the Safety and Activity of Neoad…Recrutando
PHASE1🇩🇪 Alemanha
NCT07284186 · First-in-Human Study of PLX-61639 in Locally Advanced or Met…Recrutando
PHASE1🇺🇸 Estados Unidos
NCT07334119 · Safety, Pharmacokinetics, Pharmacodynamics and Preliminary E…Recrutando
PHASE1🇦🇺 Austrália
NCT06846346 · Testing Ivonescimab in Combination With Chemotherapy in Adva…Recrutando
PHASE2🇫🇷 França
NCT07223424 · Patient Preference for Subcutaneous vs. Intravenous Immune T…Recrutando
PHASE2🇺🇸 Estados Unidos
NCT07182149 · A Phase 1 Study of NRM-823 in Participants With Locally Adva…Recrutando
PHASE1🇺🇸 Estados Unidos
NCT07159711 · Evaluation of Seismocardiography(SCG) for Assessing Fitness …Recrutando
🇬🇧 Reino Unido
NCT06161818 · Total Neoadjuvant Therapy for Lymph Node-positive Adenocarci…Recrutando
PHASE2🇳🇱 Países Baixos
NCT07090499 · A Study to Learn About the Study Medicine Called PF-08046876…Recrutando
PHASE1🇨🇦 Canadá · 🇨🇳 China · Puerto Rico +3
NCT06523374 · A Study of Barrett's Esophagus Patients to Investigate Quali…Recrutando
NA🇧🇪 Bélgica · 🇩🇰 Dinamarca · 🇫🇷 França +3
NCT07359443 · Combination of Chemotherapy and Adaptive MR-Guided Radiother…Recrutando
PHASE1🇳🇱 Países Baixos
NCT07675967 · Clonal Hematopoiesis Chemotherapy and Radiation Effects Stud…Recrutando
🇺🇸 Estados Unidos
NCT06657144 · A Study of CHS-114 (Tagmokitug) in Combination With Toripali…Recrutando
PHASE1🇹🇼 Taiwan · 🇺🇸 Estados Unidos
NCT06687603 · Multi-Site Detection of Barrett's Esophagus in Patients With…Recrutando
NA🇺🇸 Estados Unidos
NCT06687876 · Metformin as a Metabolic Intervention in Oesophageal Adenoca…Recrutando
PHASE2🇳🇱 Países Baixos
NCT07125248 · Outcomes of a Single Chest Drain vs Two DrainsRecrutando
NAPakistan
NCT06289374 · Longitudinal Assessment of Biomarkers After Oesophagogastric…Recrutando
🇬🇧 Reino Unido
NCT06532734 · Barrett's Esophagitis in Anorexia Nervosa Binge/Purge Subtyp…Recrutando
🇺🇸 Estados Unidos
NCT05563766 · A Phase II Trial to Evaluate the Effect of Itraconazole on P…Recrutando
PHASE2🇺🇸 Estados Unidos
NCT06623396 · A Study of Mesothelin-Targeted CAR T-Cell Therapy in People …Recrutando
PHASE1🇺🇸 Estados Unidos
NCT06044311 · Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemor…Recrutando
PHASE2🇺🇸 Estados Unidos
NCT06324357 · Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertin…Recrutando
PHASE1, PHASE2🇧🇪 Bélgica · 🇨🇳 China · 🇫🇷 França +7
NCT06203600 · Adding Nivolumab to Usual Treatment for People With Advanced…Recrutando
PHASE2, PHASE3🇺🇸 Estados Unidos
NCT07375420 · Will a Pre-therapy Exercise Intervention Improve the Outcome…Recrutando
NA🇬🇧 Reino Unido
NCT06340711 · Study of Suratadenoturev (OBP-301) in Combination With Pembr…Recrutando
PHASE2🇺🇸 Estados Unidos
NCT04939051 · Obeticholic Acid for Prevention in Barrett's EsophagusRecrutando
PHASE2🇺🇸 Estados Unidos
NCT06078709 · Preoperative Hypofractionated Radiotherapy With FOLFOX for E…Recrutando
PHASE2🇺🇸 Estados Unidos
NCT06071845 · Assessment of a Minimally Invasive Collection Device for Mol…Recrutando
NA🇺🇸 Estados Unidos
NCT05745857 · Oral Bevacizumab-800CW and Cetuximab-800CW Administration to…Recrutando
PHASE2🇳🇱 Países Baixos
NCT05954312 · A First-in-Human (FIH) Study to Evaluate the Safety and Tole…Recrutando
PHASE1South Korea · 🇪🇸 Espanha · 🇺🇸 Estados Unidos
NCT06005493 · Study of AZD5863 in Adult Participants With Advanced or Meta…Recrutando
PHASE1, PHASE2🇨🇳 China · 🇫🇷 França · 🇯🇵 Japão +5
NCT05965999 · Lucid Registry StudyRecrutando
🇺🇸 Estados Unidos
NCT05651594 · Propranolol in Combination With Pembrolizumab and Standard C…Recrutando
PHASE2🇺🇸 Estados Unidos
NCT05677490 · mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the…Recrutando
PHASE3Puerto Rico · 🇺🇸 Estados Unidos
NCT05753748 · Surveillance vs. Endoscopic Therapy for Barrett's Esophagus …Recrutando
NA🇺🇸 Estados Unidos
NCT05642338 · A Multicenter Prospective Cohort Study Comparing Random Biop…Recrutando
🇳🇱 Países Baixos
NCT05530343 · Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sam…Recrutando
NA🇺🇸 Estados Unidos
NCT07660627 · Determining Minimal Residual Disease Using ctDNA Deep Sequen…Recrutando
NA🇨🇿 Tchéquia
NCT05188313 · TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal …Recrutando
PHASE3🇳🇱 Países Baixos
NCT05177133 · Anti-PD-1 and CapOx for the First-line Treatment of dMMR Eso…Recrutando
PHASE2🇳🇱 Países Baixos
NCT04900818 · Study of TJ033721 (Givastomig) in Subjects With Advanced or …Recrutando
PHASE1🇨🇳 China · 🇺🇸 Estados Unidos
NCT04682158 · Propranolol With Chemotherapy or Chemoradiation for Esophage…Recrutando
PHASE2🇺🇸 Estados Unidos
NCT04306458 · RAMIE Versus MIE for Resectable Esophageal Cancer, a Randomi…Recrutando
NA🇩🇪 Alemanha
NCT07309991 · Postoperative Hypoxemia Increases the Risk of Anastomotic Le…Recrutando
🇨🇳 China
NCT04615013 · NBTXR3, Chemotherapy, and Radiation Therapy for the Treatmen…Recrutando
PHASE1🇺🇸 Estados Unidos
NCT04114136 · Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malign…Recrutando
PHASE2🇺🇸 Estados Unidos
NCT04150640 · Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for H…Recrutando
PHASE2🇺🇸 Estados Unidos
NCT04389632 · A Study of Sigvotatug Vedotin in Advanced Solid TumorsRecrutando
PHASE1🇫🇷 França · South Korea · 🇪🇸 Espanha +4
NCT04290806 · Registry Platform Gastric/Esophageal Cancer (SAPHIR)Recrutando
🇩🇪 Alemanha
NCT03539822 · Cabozantinib Plus Durvalumab With or Without Tremelimumab in…Recrutando
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT03161522 · Chemotherapy With or Without Radiation or Surgery in Treatin…Recrutando
PHASE2🇺🇸 Estados Unidos
NCT03222635 · Prospective Endoscopic Follow-up of Patients With Submucosal…Recrutando
NA🇦🇺 Austrália · 🇧🇪 Bélgica · 🇩🇪 Alemanha +3
NCT00574327 · Progression of Gastroesophageal Reflux Disease and Barrett's…Recrutando
🇺🇸 Estados Unidos
NCT07212491 · Minimally Invasive Molecular Approaches for the Detection of…Por convite
🇺🇸 Estados Unidos
NCT00587314 · The Effect of Ablation Therapy on Barrett's EsophagusPor convite
🇺🇸 Estados Unidos

Outros ensaios clínicos

361 ensaios clínicos encontrados, 107 ativos.

Distribuição por fase
NCT07059611 · Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal A…Em breve
PHASE2🇺🇸 Estados Unidos
NCT07818070 · A Trial of ONO-4578 Versus Placebo in Combination With Nivol…Em breve
PHASE3
NCT07206589 · Minimally Invasive Approaches for the Diagnosis of Barrett's…Em breve
NA🇺🇸 Estados Unidos
NCT07517211 · A Prospective Study of Physical Function in Adults Who Recei…Em breve
🇺🇸 Estados Unidos
NCT07887568 · Lucid BE Biomarkers StudyEm breve
🇺🇸 Estados Unidos
NCT07260734 · AUGMENTED RESPONSE OF VOLATILE BIOMARKERS IN THE ASSESSMENT …Em breve
NCT06933966 · Evaluation of Efficacy and Safety De-escalation Versus Stand…Em breve
PHASE2🇫🇷 França
NCT07164690 · Low-Dose Radiotherapy in Patients With Advanced Esophageal S…Em breve
PHASE2
NCT06356311 · A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Adv…Ativo
PHASE3🇧🇷 Brasil · 🇧🇪 Bélgica · 🇨🇦 Canadá +21
NCT05152147 · A Study of Zanidatamab in Combination With Chemotherapy Plus…Ativo
PHASE3🇧🇷 Brasil · 🇦🇷 Argentina · 🇦🇺 Austrália +30
NCT07546812 · Study of Denikitug (GS-1811) Given Alone or With Nivolumab o…Ativo
PHASE2🇦🇺 Austrália · 🇫🇷 França · South Korea +2
NCT07663786 · Evaluation of Esophagogastric Cancer Treatment With Nivoluma…Ativo
🇳🇱 Países Baixos
NCT07021066 · Evaluate the Safety, Tolerability, Pharmacokinetics and Effi…Ativo
PHASE1🇺🇸 Estados Unidos
NCT06628310 · A Study to Evaluate the Adverse Events, Efficacy, and Optima…Ativo
PHASE2🇧🇪 Bélgica · 🇨🇦 Canadá · 🇨🇳 China +8
NCT06504615 · Observational Study of Patients Treated With Nivolumab and C…Ativo
🇫🇷 França
NCT06642506 · Oncometabolome and MALDI-MSI in Upper GI Carcinomas - Chemos…Ativo
🇩🇪 Alemanha
NCT06251973 · A Study of agenT-797 in Combination With Botensilimab, Balst…Ativo
PHASE2🇺🇸 Estados Unidos
NCT06266299 · A Study of KK2269 in Adult Participants With Solid TumorsAtivo
PHASE1🇯🇵 Japão · 🇺🇸 Estados Unidos
NCT07490340 · Trans-Oral Sampling as an Alternative Surveillance of Barret…Ativo
🇳🇱 Países Baixos
NCT05713838 · Organ Preservation With Durvalumab-based Immunotherapy in Co…Ativo
PHASE2🇩🇪 Alemanha
NCT05480384 · Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Pa…Ativo
PHASE2🇺🇸 Estados Unidos
NCT05945823 · Phase 2 Futibatinib in Combination With PD-1 Antibody Based …Ativo
PHASE2🇫🇷 França · 🇩🇪 Alemanha · 🇪🇸 Espanha +1
NCT05476796 · Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tip…Ativo
PHASE2🇫🇷 França
NCT05078047 · Study Comparing the Standard Administration of IO Versus the…Ativo
PHASE3🇫🇷 França
NCT04929392 · Chemoradiation and Pembrolizumab Followed by Pembrolizumab a…Ativo
PHASE2🇺🇸 Estados Unidos
NCT04554771 · Blood-borne Assessment of Stromal Activation in Esophageal A…Ativo
PHASE2🇳🇱 Países Baixos
NCT04430738 · Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherap…Ativo
PHASE2🇯🇵 Japão · 🇺🇸 Estados Unidos
NCT04295811 · Efficacy of EsoGuard Assay on Esophageal Surface Cells Colle…Ativo
NA🇳🇱 Países Baixos · 🇺🇸 Estados Unidos
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
0 papers (10 anos)
#1

Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial.

BMJ (Clinical research ed.)2026 Mar 12

To compare camrelizumab plus capecitabine and oxaliplatin followed by camrelizumab plus apatinib (camre+CAPOX followed by camre+apa), CAPOX alone, and camrelizumab plus CAPOX followed by camrelizumab (camre+CAPOX followed by camre) as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma. Randomised, open label, phase 3 study. 75 hospitals in China, 13 March 2019 to 16 August 2021. 885 adults (≥18 years) with previously untreated, human epidermal growth factor receptor 2 (HER2) negative, unresectable, locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Patients were randomised (2:2:1) to receive camre+CAPOX followed by camre+apa, CAPOX only, or camre+CAPOX followed by camre, stratified by Eastern Cooperative Oncology Group performance status, peritoneal metastasis, and programmed death ligand 1 (PD-L1) combined positive score. Assignment to camre+CAPOX followed by camre was introduced midway through enrolment. The primary endpoint was overall survival for camre+CAPOX followed by camre+apa versus CAPOX alone in the PD-L1 positive population (combined positive score >1) and the overall population who received at least one dose of study drug. Comparisons of camre+CAPOX followed by camre versus CAPOX alone and of camre+CAPOX followed by camre+apa versus camre+CAPOX-camre were descriptive. Safety was assessed in all patients who received at least one dose of study drug. 352 patients received camre+CAPOX followed by camre+apa, 349 received CAPOX alone, and 177 received camre+CAPOX followed by camre. At the time of data cut off, 454 of 592 (76.7%) deaths had occurred in the PD-L1 positive population and 709 of 878 (80.8%) in the overall population. Overall survival was longer with camre+CAPOX followed by camre+apa than with CAPOX alone in the PD-L1 positive population (median 15.0 v 12.5 months; hazard ratio 0.80 (95% CI 0.65 to 0.98); one sided P=0.02) and in the overall population (median 13.5 v 12.1 months; hazard ratio 0.80 (0.68 to 0.94); one sided P=0.004). Use of camre+CAPOX followed by camre also showed longer overall survival versus CAPOX in the PD-L1 positive population (median 15.3 v 12.5 months; hazard ratio 0.76 (0.58 to 0.97); one sided nominal P=0.01) and overall population (median 14.2 v 12.1 months; hazard ratio 0.80 (0.65 to 0.98); one sided nominal P=0.02). No overall survival benefit was observed with camre+CAPOX followed by camre+apa versus camre+CAPOX followed by camre. Treatment related adverse events of grade ≥3 occurred in 239 of 352 (67.9%) patients in the camre+CAPOX followed by camre+apa group, 158 of 349 (45.3%) in the CAPOX alone group, and 83 of 177 (46.9%) in the camre+CAPOX followed by camre group. Initial treatment with camrelizumab plus CAPOX followed by camrelizumab based maintenance was associated with longer overall survival than CAPOX alone in human epidermal growth factor receptor 2 (HER2) negative, unresectable, locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Exploratory comparisons between the two camrelizumab based regimens showed no additional survival benefit, with higher rates of treatment related adverse events of grade ≥3 and treatment discontinuations when apatinib was added during maintenance. ClinicalTrials.gov NCT03813784.

#2

Novel Methylation-Based Model for Accurate Diagnosis of Upper Mediastinal Lymph Node Metastasis in Esophagogastric Junction Adenocarcinoma.

Cancer science2026 Jan

Even after surgical resection, the prognosis is poor for patients with esophagogastric junction adenocarcinoma who develop upper mediastinal lymph node metastasis. Moreover, the current preoperative diagnostic accuracy for upper mediastinal lymph node metastasis remains inadequate, which complicates treatment planning. To enhance diagnostic precision and facilitate personalized therapeutic strategies, we aimed to develop a novel diagnostic model that integrates a DNA methylation panel with conventional clinical parameters. First, genome-wide methylation profiling of 69 tumors identified seven CpG sites significantly associated with upper mediastinal lymph node involvement. We then evaluated a methylation panel based on these markers in two independent cohorts comprising a total of 133 treatment-naïve patients. The methylation panel alone achieved moderate diagnostic performance (AUC 0.71, 95% CI 0.52-0.91), whereas its integration with clinical data substantially improved accuracy (training cohort: AUC 0.87, 95% CI 0.75-0.99). Applying the same model formula to an independent pretreatment validation cohort confirmed its robustness (AUC 0.85, 95% CI 0.70-1.00). Furthermore, the methylation panel was identified as an independent prognostic factor for overall survival (p < 0.01). Finally, to facilitate clinical implementation, the integrated model was formalized as a nomogram. In summary, this novel diagnostic model enables highly accurate detection of upper mediastinal lymph node metastasis in esophagogastric junction adenocarcinoma, with the potential to optimize treatment decisions and reduce the need for invasive procedures, thereby contributing to precision oncology.

#3

Neoadjuvant Therapy for Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma: Current Status, Challenges, and Future Perspectives.

Cancer medicine2026 Mar

Gastric cancer remains a leading cause of cancer-related mortality worldwide, with locally advanced gastric/gastroesophageal junction adenocarcinoma posing significant therapeutic challenges. Neoadjuvant therapy has emerged as a critical strategy to improve surgical outcomes and long-term survival by reducing tumor burden and eradicating micrometastases. This systematic review integrates evidence from more than 100 clinical trials and 20 meta-analyses published in recent years. It focuses on new advances in neoadjuvant therapies for gastric cancer, including chemotherapy, radiotherapy, immunotherapy, and targeted therapies, while highlighting emerging combination strategies and unresolved clinical dilemmas.

#4

Efficacy and safety of cadonilimab combined with chemotherapy for gastric or gastroesophageal junction adenocarcinoma: a single-arm meta-analysis.

Frontiers in immunology2026

Immune checkpoint inhibitors (ICIs) combined with chemotherapy have become an important area of clinical investigation in the gastric cancer (GC) and gastroesophageal junction cancer (GEJC). In recent years, bispecific antibody therapies have been increasingly explored, including cadonilimab, a programmed death-1/cytotoxic T-lymphocyte-associated antigen 4 (PD-1/CTLA-4) bispecific antibody. Several phase II studies have reported early signals of antitumor activity with cadonilimab, prompting clinical interest in this strategy. However, treatment outcomes vary across studies, and a systematic assessment of the efficacy and safety of cadonilimab plus chemotherapy remains limited. This study aimed to evaluate the efficacy and safety profile of cadonilimab in combination with chemotherapy for gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (G/GEJ adenocarcinoma) through a single-arm meta-analysis. A systematic search was conducted in PubMed, Embase, the Cochrane Library, Web of Science, and ClinicalTrials.gov to identify eligible studies published up to July 20, 2025. A single-arm meta-analysis was performed to pool and evaluate the objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), pathological complete response (pCR), and the incidence of grade ≥3 treatment-related adverse events (TRAEs). A total of four clinical studies involving 182 patients were included. The pooled estimates were an ORR of 57% (95% CI: 48%-66%), a DCR of 97% (95% CI: 84%-100%), a pCR of 23% (95% CI: 12%-35%), and a median PFS of 7.98 months (95% CI: 6.38-9.57). The overall incidence of grade ≥3 TRAEs was 35% (95% CI: 7%-63%). In subgroup analyses, the incidence of grade ≥3 TRAEs appeared lower in the neoadjuvant setting than in the first-line setting (29% [95% CI: 28%-40%] vs 53% [95% CI: 45%-60%]). The most frequently reported adverse events included nausea (72%), vomiting (60%), neutropenia (51%), and leukopenia (45%). Based on available early-phase evidence, cadonilimab plus chemotherapy showed antitumor activity with a manageable safety profile in G/GEJ adenocarcinoma. Further large-scale, high-quality randomized controlled trials are needed to validate these findings and define the optimal treatment strategy. https://www.crd.york.ac.uk/PROSPERO, identifier CRD420251089855.

#5

Is pathological complete response a surrogate for overall survival in neoadjuvant clinical trials for gastroesophageal adenocarcinoma?

European journal of cancer (Oxford, England : 1990)2026 Mar 26

Pathologic complete response (pCR) is frequently used as a surrogate endpoint in neoadjuvant gastroesophageal adenocarcinoma (GEA) trials, yet its validity in predicting overall survival (OS) remains uncertain. This systematic review and meta-analysis, follows PRISMA and ReSEEM guidelines, and evaluates pCR as a surrogate for OS in randomized controlled trials (RCTs) of neoadjuvant therapy for GEA. Randomized trials enrolling patients with resectable distal esophageal, gastroesophageal junction (GEJ), or gastric adenocarcinoma were included if both pCR and OS were reported. Individual-level surrogacy was assessed by correlating pCR rates with median OS across trial arms; trial-level surrogacy was evaluated by correlating treatment effects on pCR (odds ratios) with treatment effects on OS (hazard ratios) using weighted linear regression and calculating the coefficient of determination (R²). Twenty-six RCTs including 7452 patients were analyzed. Overall, pCR showed no meaningful correlation with OS at the individual-level (R² = 0.006; p = 0.210), and treatment effects on pCR explained little of the variability in OS effects at the trial level (R² = 0.060; p = 0.206). Most trials evaluated cytotoxic chemotherapy or chemoradiotherapy. Surrogacy varied by subgroup, being strong for esophageal adenocarcinoma (R² = 0.886; p < 0.001), moderate for gastric cancer (R² = 0.386; p = 0.041), and absent for GEJ trials. Trials incorporating radiotherapy demonstrated strong surrogacy, whereas chemotherapy-only trials did not. The interpretation of pCR results in gastroesophageal adenocarcinoma trials requires caution. Surrogacy might need to be reassessed in the upcoming immunotherapy trials.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC10 artigos no totalmostrando 198

2026

Neoadjuvant Therapy for Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma: Current Status, Challenges, and Future Perspectives.

Cancer medicine
2026

Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial.

BMJ (Clinical research ed.)
2026

Efficacy and safety of cadonilimab combined with chemotherapy for gastric or gastroesophageal junction adenocarcinoma: a single-arm meta-analysis.

Frontiers in immunology
2026

Is pathological complete response a surrogate for overall survival in neoadjuvant clinical trials for gastroesophageal adenocarcinoma?

European journal of cancer (Oxford, England : 1990)
2026

Cost-effectiveness of perioperative durvalumab plus FLOT for resectable gastric and gastroesophageal junction adenocarcinoma in the United States.

Frontiers in immunology
2026

Early Recurrence of Esophagogastric junction adenoCarcinoma after Surgery: a multicentre analysis of risk factors (ERECS Trial).

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
2025

The Evolving Paradigm of Esophageal and Esophagogastric Junction Adenocarcinoma: Current Insights, Emerging Therapies, and Future Directions.

Journal of cancer science and clinical therapeutics
2026

Treatment patterns, health care resource utilization and costs, and clinical outcomes among older adult patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.

Journal of managed care &amp; specialty pharmacy
2026

Ocular Safety Evaluation of Bemarituzumab in FGFR2b-Overexpressing Gastroesophageal Adenocarcinoma: A 42-Week Follow-Up Study.

Ocular immunology and inflammation
2025

Clonal cell states link gastroesophageal junction tissues with metaplasia and cancer.

Nature communications
2026

Comparative short-term outcomes of peri-operative immunotherapy and targeted therapy for gastric and gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
2025

Risk factors and prediction model for submucosal invasion in early protruding-type esophagogastric junction adenocarcinoma: conventional endoscopy combines with endoscopic ultrasonography.

BMC gastroenterology
2026

Does perioperative FLOT increase cure rates in resectable esophageal adenocarcinoma? A mixture cure model analysis.

British journal of cancer
2025

The Relevance of Lymphadenectomy Extension to the Right Paratracheal Space in the Treatment of Esophagogastric Junction Adenocarcinoma: A Retrospective Bicentric Study.

Current oncology (Toronto, Ont.)
2026

Diagnostic Approach to Early Barrett's Neoplasia: Western Perspective.

Digestion
2025

Toward standardization in esophageal cancer surgery: patterns of practice across high-volume European centers.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
2025

CLDN18.2 expression in gastroesophageal adenocarcinoma: prevalence, heterogeneity, and prognostic implications in Spanish patients.

Virchows Archiv : an international journal of pathology
2026

Real-world comparison between neoadjuvant FLOT therapy and DCF therapy for resectable esophagogastric junction adenocarcinoma.

Esophagus : official journal of the Japan Esophageal Society
2025

Intratumoral regulatory T cells are associated with treatment response to neoadjuvant chemotherapy and prognosis in gastroesophageal adenocarcinoma.

Oncoimmunology
2025

Strategies to prevent Barrett's esophagus associated esophageal adenocarcinoma.

World journal of gastroenterology
2025

First-line pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: Health-related quality of life from the randomized phase III KEYNOTE-859 trial.

European journal of cancer (Oxford, England : 1990)
2026

Novel Methylation-Based Model for Accurate Diagnosis of Upper Mediastinal Lymph Node Metastasis in Esophagogastric Junction Adenocarcinoma.

Cancer science
2025

Perioperative pembrolizumab, trastuzumab and FLOT in HER2-positive localized esophagogastric adenocarcinoma: a phase 2 trial.

Nature medicine
2025

Beamion BCGC-1: phase Ib/II trial of zongertinib for advanced HER2-positive breast or gastroesophageal cancers.

Future oncology (London, England)
2025

Comparison of Pretreatment Strategies for cT2cN0 Staged Adenocarcinoma of the Esophagus and the Gastroesophageal Junction: A European High-Volume Center Cohort Analysis.

Annals of surgical oncology
2026

Endoscopic Evaluation of the Gastroesophageal Junction and Diagnosis of Barrett's Esophagus.

Digestion
2025

Near-Infrared Photoimmunotherapy Targeting Esophagogastric Junction Adenocarcinoma With Fully Human Anti-EpCAM Antibody.

Cancer science
2025

Human Epidermal Growth Factor Receptor 2 [HER-2/neu] Amplification and Microsatellite Stable Status in Gastric and Gastroesophageal Adenocarcinoma: Assessing Frequency and Prognostic Implications at the Cancer Institute of Iran.

Cancer reports (Hoboken, N.J.)
2025

Claudin 18.2 and Other Therapeutic Biomarkers in Gastric and Gastroesophageal Junction Adenocarcinomas.

The American journal of surgical pathology
2025

FLOT Versus CROSS-What Is the Optimal Therapeutic Approach for Locally Advanced Adenocarcinoma of the Esophagus and the Esophagogastric Junction?

Cancers
2025

First-line pembrolizumab plus chemotherapy for participants in Japan with gastric or gastroesophageal junction adenocarcinoma: subgroup analysis of the phase 3 KEYNOTE-859 study.

International journal of clinical oncology
2025

Longitudinal circulating tumor DNA analysis during treatment of locally advanced resectable gastric or gastroesophageal junction adenocarcinoma: the PLAGAST prospective biomarker study.

Nature communications
2025

Analytical and Clinical Performance of the VENTANA CLDN18 (43-14A) RxDx Assay in Gastric and Gastroesophageal Junction Adenocarcinoma Tissue Samples in SPOTLIGHT and GLOW.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
2025

Efficacy of perioperative and neoadjuvant therapies in gastric and gastroesophageal junction adenocarcinoma: a network meta-analysis.

The oncologist
2025

DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B.

Nature communications
2025

Q-TWiST analysis of first-line nivolumab plus chemotherapy versus chemotherapy in patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma from CheckMate 649: 4-year follow-up results.

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
2025

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the RATIONALE-305 study.

Current medical research and opinion
2025

Cost-effectiveness analysis of first-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma.

Frontiers in immunology
2025

Zolbetuximab-clzb: Targeting Claudin 18.2 in Advanced Gastric and Gastroesophageal Adenocarcinoma.

The Annals of pharmacotherapy
2025

First-line immune checkpoint inhibitors with chemotherapy in advanced gastric and gastroesophageal junction adenocarcinoma: a meta-analysis of phase 3 trials.

Frontiers in immunology
2025

Regorafenib combined with irinotecan as second-line treatment in metastatic gastro-oesophageal adenocarcinomas: results of PRODIGE 58-UCGI35-REGIRI Unicancer randomised phase II study.

ESMO open
2025

Zanidatamab monotherapy or combined with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma: a phase 1 trial.

Nature communications
2025

Biomarker-Driven Approach to the Treatment of Metastatic Gastric or Gastroesophageal Adenocarcinoma.

Journal of the National Comprehensive Cancer Network : JNCCN
2025

Detection of Barrett's Esophagus Prior to Development of Esophageal and Esophagogastric Junction Adenocarcinoma.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
2025

TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trial.

The Lancet. Oncology
2025

The Impact of Peri-Operative Nutritional Status on Survival in Gastroesophageal Adenocarcinoma.

Current oncology (Toronto, Ont.)
2025

Long-term trends in the clinical management and outcomes of patients with gastroesophageal cancer in Norway.

Acta oncologica (Stockholm, Sweden)
2025

Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: A Phase II Study.

Cancer medicine
2025

Gastric Cardiac Carcinoma: Recent Progress in Clinicopathology, Prognosis, and Early Diagnosis.

Journal of digestive diseases
2025

Associations between body mass index and gastroesophageal cancer incidence and mortality: novel insights from a nationwide registry-based cohort study.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
2025

Prognostic significance of subcarinal lymph node involvement in patients with Siewert type I and II gastro-esophageal junctional adenocarcinoma: an analysis of 698 patients undergoing Ivor-Lewis esophagectomy.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
2025

Perioperative tislelizumab plus chemotherapy for locally advanced gastroesophageal junction adenocarcinoma (NEOSUMMIT-03): a prospective, nonrandomized, open-label, phase 2 trial.

Signal transduction and targeted therapy
2025

Effects of perioperative treatment of resectable adenocarcinoma of esophagogastric junction by immunotherapy (Adebrelimab) combined with chemotherapy (XELOX): protocol for a single-center, open-labeled study (AEGIS trial, neoadjuvant immunochemotherapy).

BMC cancer
2025

Is it time to retire preoperative radiation for localized esophageal and gastro-esophageal adenocarcinoma?

The oncologist
2025

First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.

Nature medicine
2025

Study on the metastatic mechanism of LINC00115 in adenocarcinoma of the Esophagogastric junction.

Human molecular genetics
2024

Canadian Consensus Recommendations for Predictive Biomarker Testing in Gastric and Gastroesophageal Junction Adenocarcinoma.

Current oncology (Toronto, Ont.)
2025

Expression of therapy target molecules in esophagogastric junction and Barrett's adenocarcinoma.

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
2025

Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO.

Annals of oncology : official journal of the European Society for Medical Oncology
2025

Neoadjuvant cadonilimab plus FLOT chemotherapy in locally advanced gastric/gastroesophageal junction adenocarcinoma: A multicenter, phase 2 study.

Med (New York, N.Y.)
2024

[Claudine 18.2: A new therapeutic target in digestive cancers].

Bulletin du cancer
2025

More May Not Be Better: Comparison of Oncologic Outcomes Following Induction Chemotherapy Plus Chemoradiation and Chemoradiation Alone for Esophageal Adenocarcinoma.

Journal of surgical oncology
2025

Accuracy of the preoperative estimation of esophageal invasion length of adenocarcinoma of the esophagogastric junction and its discrepancy with the pathological measurement.

Surgery today
2024

Chemotherapy effects on mitochondrial function in adipose tissue in oesophageal and gastroesophageal junction adenocarcinomas with or without associated cachexia: protocol for a prospective, comparative observational study (ChiFMeOE).

BMJ open
2024

Evolving Treatment Landscape for Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma.

Current oncology reports
2025

FOXP3+/CD8+ ratio associated with aggressive behavior in RUNX3-methylated diffuse esophagogastric junction tumor.

Cancer science
2025

DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2024

Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma: a series of patient-level meta-analyses in different programmed death-ligand 1 subgroups.

ESMO open
2024

PD-1/PD-L1 Inhibitors in Combination With Chemo or as Monotherapy vs. Chemotherapy Alone in Advanced, Unresectable HER2-Negative Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Meta-Analysis.

Clinical oncology (Royal College of Radiologists (Great Britain))
2024

Tumor thickness is associated with metastasis in patients with submucosal invasive adenocarcinoma of the esophagogastric junction.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
2024

Combination of immune checkpoint inhibitors and radiotherapy in locally advanced esophagogastric junction adenocarcinoma: A review.

Cancer
2024

Predictors of early recurrence of oesophagogastric adenocarcinoma after neoadjuvant FLOT.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
2024

Clinical Trials in Gastroesophageal Cancers: An Analysis of the Global Landscape of Interventional Trials From ClinicalTrials.gov.

JCO global oncology
2024

Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trials.

ESMO open
2024

Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma.

Nature communications
2024

The Landscape and Prognosis of Microsatellite Stable (MSS) Esophageal, Gastro-Esophageal Junction and Gastric Adenocarcinomas with High Tumor Mutation Burden (TMB).

Cancer investigation
2024

Optimal Treatment Strategies for cT2 Staged Adenocarcinoma of the Esophagus and the Gastroesophageal Junction: A Multinational, High-volume Center Retrospective Cohort Analysis.

Annals of surgery
2024

Efficacy and safety of ramucirumab for gastric or gastro-esophageal junction adenocarcinoma: a systematic review and meta-analysis.

European journal of clinical pharmacology
2024

Claudin-18.2 Immunohistochemical Evaluation in Gastric and Gastroesophageal Junction Adenocarcinomas to Direct Targeted Therapy: A Practical Approach.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
2024

Preoperative Chemoradiotherapy vs Chemotherapy for Adenocarcinoma of the Esophagogastric Junction: A Network Meta-Analysis.

JAMA network open
2024

Characteristics of auto-quantified tumor-infiltrating lymphocytes and the prognostic value in adenocarcinoma of the esophagogastric junction, gastric adenocarcinoma, and esophageal squamous cell carcinoma.

Aging
2024

Diffuse-Type Histology Is Prognostic for All Siewert Types of Gastroesophageal Adenocarcinoma.

Journal of gastric cancer
2024

Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial.

Nature medicine
2024

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial.

BMJ (Clinical research ed.)
2024

Histopathologic response in patients with curative resection with D2 dissection following neoadjuvant treatment for locally advanced gastric and esophagogastric junction adenocarcinoma.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
2024

Trifluridine/tipiracil + oxaliplatin ± nivolumab vs FOLFOX ± nivolumab in HER2 negative advanced oesogastric adenocarcinoma: The PRODIGE73-UCGI40-LOGICAN trial.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
2024

Challenges and considerations in interpreting the age-dependent benefit of neoadjuvant treatment for adenocarcinoma of the esophagus and gastroesophageal junction.

International journal of surgery (London, England)
2024

Molecular Landscape and Clinical Implication of CCNE1-amplified Esophagogastric Cancer.

Cancer research communications
2024

Phenotypic immune characterization of gastric and esophageal adenocarcinomas reveals profound immune suppression in esophageal tumor locations.

Frontiers in immunology
2024

Real-World Effectiveness and Safety of Ramucirumab as a Second-Line Treatment for Patients with Unresectable Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma in Japan and South Korea: A Systematic Literature Review.

Advances in therapy
2024

[High LINC00626 expression promotes esophagogastric junction adenocarcinoma metastasis: the mediating role of the JAK1/STAT3/KHSRP axis].

Nan fang yi ke da xue xue bao = Journal of Southern Medical University
2024

A prospective phase II clinical trial of total neoadjuvant therapy for locally advanced gastric cancer and gastroesophageal junction adenocarcinoma.

Scientific reports
2024

Siewert II esophagogastric junction adenocarcinoma: Still searching for the right treatment transabdominal or transthoracic surgical approaches?

Asian cardiovascular &amp; thoracic annals
2024

Esophageal adenocarcinoma heterogeneity in clinicopathology and prognosis: A single center longitudinal study of 146 cases over a 20-year period.

Annals of diagnostic pathology
2024

Preoperative ultrasound-guided dual localization with titanium clips and carbon nanoparticles for predicting the surgical approach and guiding the resection of Siewert type II esophagogastric junction adenocarcinoma.

Journal of cancer research and clinical oncology
2024

Preoperative docetaxel, cisplatin, and 5-fluorouracil for resectable locally advanced esophageal and esophagogastric junctional adenocarcinoma.

Esophagus : official journal of the Japan Esophageal Society
2024

Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for the treatment of locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): an open-label, randomized, phase 2 clinical trial.

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
2024

Endoscopic Characteristics of Early Gastroesophageal Junction Adenocarcinomas and Assessment for Invasion Depth: A Case Series Study.

The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
2024

Multicenter analysis on the value of standard (chemo)radiotherapy in elderly patients with locally advanced adenocarcinoma of the esophagus or gastroesophageal junction.

Radiation oncology (London, England)
2024

[Interpretation of Chinese expert consensus on the surgical treatment for adenocarcinoma of esophagogastric junction(2024 edition)].

Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
2024

[Chinese expert consensus on the surgical treatment for adenocarcinoma of esophagogastric junction (Edition 2024)].

Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
2024

A proactive financial navigation intervention in patients with newly diagnosed gastric and gastroesophageal junction adenocarcinoma.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
2025

Tumor stroma ratio, tumor stroma maturity, tumor-infiltrating immune cells in relation to prognosis, and neoadjuvant therapy response in esophagogastric junction adenocarcinoma.

Virchows Archiv : an international journal of pathology
2024

Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trials.

BMC cancer
2024

First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2024

Fruquintinib plus oxaliplatin combined with S-1 (SOX) as neoadjuvant therapy for locally advanced gastric cancer (GC) or gastro-oesophageal junction adenocarcinoma (GEJ): a multicentre, phase II, single-arm, open-label clinical trial (FRUTINEOGA) protocol.

BMJ open
2024

Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial.

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
2024

Associations of long non-coding RNAs HOTAIR, LINC00951, POLR2E and HULC polymorphisms with the risk of esophageal and esophagogastric junction cancer in a western population: a case-control study.

Molecular biology reports
2024

Updated German guideline on diagnosis and treatment of squamous cell carcinoma and adenocarcinoma of the esophagus.

United European gastroenterology journal
2024

Current and Future Biomarkers in Esophagogastric Adenocarcinoma.

Journal of gastrointestinal cancer
2024

Endoscopic Surveillance of Intestinal Metaplasia of the Esophagogastric Junction: A Decision Modeling Analysis.

The American journal of gastroenterology
2024

[Comparison of short-term safety of two anastomotic techniques when resecting Siewert type II adenocarcinoma of the esophagogastric junction: a multicenter retrospective cohort study].

Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
2024

Early endpoints of a randomized phase II trial of preoperative chemotherapy with S-1/CDDP with or without trastuzumab followed by surgery for HER2-positive resectable gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301C (Trigger Study).

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
2024

Management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction: the Neo-AEGIS trial - Authors' reply.

The lancet. Gastroenterology &amp; hepatology
2024

Management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction: the Neo-AEGIS trial.

The lancet. Gastroenterology &amp; hepatology
2024

Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.

Nature medicine
2024

NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma.

British journal of cancer
2024

Clinical features and outcomes of advanced HER2+ esophageal/GEJ cancer with brain metastasis.

ESMO open
2024

[Pembrolizumab with trastuzumab and chemotherapy in advanced or metastatic gastric or gastroesophageal junction adenocarcinomas with surexpression of HER2 and CPS≥1].

Bulletin du cancer
2023

Efficacy and safety of XELOX combined with anlotinib and penpulimab vs XELOX as an adjuvant therapy for ctDNA-positive gastric and gastroesophageal junction adenocarcinoma: a protocol for a randomized, controlled, multicenter phase II clinical trial (EXPLORING study).

Frontiers in immunology
2023

Effect of different surgical approaches on the survival and safety of Siewert type II esophagogastric junction adenocarcinoma: a systematic review and meta-analysis.

BMC cancer
2024

Protocol digest of a randomized controlled adaptive Phase II/III trial of neoadjuvant chemotherapy for Japanese patients with oesophagogastric junction adenocarcinoma: Japan Clinical Oncology Group Study JCOG2203 (NEO-JPEG).

Japanese journal of clinical oncology
2024

Concise Commentary: It's All Downhill from Here-How Diagnostic and Therapeutic Advances May Decrease the Incidence Rates of Gastroesophageal Junction and Esophageal Adenocarcinoma.

Digestive diseases and sciences
2024

Population Based Time Trends in the Epidemiology and Mortality of Gastroesophageal Junction and Esophageal Adenocarcinoma.

Digestive diseases and sciences
2024

Histology Shift in Esophageal Cancer Between Biopsies and Resections After Neoadjuvant Therapy: A Pilot Study.

International journal of surgical pathology
2024

Total neoadjuvant therapy in oesophageal and gastro-oesophageal junctional adenocarcinoma.

British journal of cancer
2023

Chemotherapy and Immune Checkpoint Blockade for Gastric and Gastroesophageal Junction Adenocarcinoma.

JAMA oncology
2023

The correlation between the margin of resection and prognosis in esophagogastric junction adenocarcinoma.

World journal of surgical oncology
2023

Diagnosis and management of Barrett esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Guideline.

Endoscopy
2023

Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: Analysis of Number Needed To Treat and Number Needed To Harm.

Clinical therapeutics
2023

Relationship between the number of dissected lymph node and the pathological staging in esophagogastric junction adenocarcinoma.

Asian journal of surgery
2023

Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial.

The lancet. Gastroenterology &amp; hepatology
2023

Cost-effectiveness analysis of nivolumab plus chemotherapy vs chemotherapy for patients with unresectable advanced or metastatic HER2-negative gastric or gastroesophageal junction or esophageal adenocarcinoma in Japan.

Journal of gastroenterology
2023

Age-dependent benefit of neoadjuvant treatment in adenocarcinoma of the esophagus and gastroesophageal junction: a multicenter retrospective observational study of young versus old patients.

International journal of surgery (London, England)
2023

Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2023

Her2 low (but not negative): the newest biomarker on the block for gastro-oesophageal adenocarcinoma.

Journal of clinical pathology
2023

[A Case of Advanced Esophagogastric Junction Adenocarcinoma with Enlarged Lymph Node Metastases of the Middle Mediastinum and Intraperitoneal That Exhibited pCR by Preoperative SOX Therapy].

Gan to kagaku ryoho. Cancer &amp; chemotherapy
2023

Clinical characteristics and prognostic outcomes for adenocarcinoma of esophagogastric junction in early-onset patients: a population-based appraisal.

Journal of cancer research and clinical oncology
2023

Randomized controlled trial in gastric or gastroesophageal junction adenocarcinoma undergoing systemic therapy over two decades.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
2023

Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial.

Nature communications
2023

Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G).

BMC cancer
2023

Histology-Based Prediction of Therapy Response to Neoadjuvant Chemotherapy for Esophageal and Esophagogastric Junction Adenocarcinomas Using Deep Learning.

JCO clinical cancer informatics
2023

Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.

Nature medicine
2023

Impact of the Surgical Approach for Neoadjuvantly Treated Gastroesophageal Junction Type II Tumors: A Multinational, High-volume Center Retrospective Cohort Analysis.

Annals of surgery
2023

Novel Staging Schemes for Siewert Type II Esophagogastric Junction Adenocarcinoma: A Real-World Data Cohort Study from SEER Database.

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
2023

ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research
2023

Serum Interleukin 6 Level is Associated With Overall Survival and Treatment Response in Gastric and Gastroesophageal Junction Cancer.

Annals of surgery
2023

[Efficacy of machine learning models versus Cox regression model for predicting prognosis of esophagogastric junction adenocarcinoma].

Nan fang yi ke da xue xue bao = Journal of Southern Medical University
2023

Nomogram for predicting the likelihood of liver metastases at initial diagnosis in patients with Siewert type II gastroesophageal junction adenocarcinoma.

Scientific reports
2023

Incidence, clinicopathological features, and clinical outcomes of low HER2 expressed, inoperable, advanced, or recurrent gastric/gastroesophageal junction adenocarcinoma.

ESMO open
2023

Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415).

BMC cancer
2023

Efficacy of PD-1 Inhibitors in First-Line Treatment for Advanced Gastroesophageal Junction and Gastric Cancer by Subgroups: A Systematic Review and Meta-Analysis.

Chemotherapy
2023

A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma.

Cancer medicine
2023

Accurate Preoperative Evaluation of the Location of Esophagogastric Junction Adenocarcinoma Using Positron Emission Tomography-Computed Tomography.

The American surgeon
2023

FLOT or CROSS for gastroesophageal junction cancers-is the debate over yet?

Chinese clinical oncology
2023

Advancing immunotherapy in gastroesophageal cancer through rational combinations and biomarkers.

Immunotherapy
2023

Preoperative chemoradiotherapy or perioperative chemotherapy for patients with gastro-oesophageal junction adenocarcinoma.

The Lancet. Oncology
2023

Extension of resection after positive intraoperative pathology during surgery for gastric and gastroesophageal junction adenocarcinoma: a retrospective cohort study.

International journal of surgery (London, England)
2023

Long-Term Postsurgical Outcomes of Neoadjuvant Chemoradiation (CROSS) Versus Chemotherapy (FLOT) for Multimodal Treatment of Adenocarcinoma of the Esophagus and the Esophagogastric Junction.

Annals of surgical oncology
2023

Atypical presentation in adolescence of a gastroesophageal junction adenocarcinoma.

Revista de gastroenterologia de Mexico (English)
2023

Relevance of Subcarinal Lymph Node Dissection for Gastroesophageal Junction Adenocarcinoma.

The Journal of surgical research
2023

Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study.

BMC medicine
2023

Detection of a Novel MSI2-C17orf64 Transcript in a Patient with Aggressive Adenocarcinoma of the Gastroesophageal Junction: A Case Report.

Genes
2023

Artificial intelligence for tumour tissue detection and histological regression grading in oesophageal adenocarcinomas: a retrospective algorithm development and validation study.

The Lancet. Digital health
2023

Hand-sewn esophagojejunostomy in transthoracic single-port assisted laparoscopic esophagogastrectomy for Siewert type II adenocarcinoma of the esophagogastric junction with esophageal invasion > 3 cm.

Surgical endoscopy
2023

[Feasibility of a single-port thoracoscopy-assisted five-step laparoscopic procedure via transabdominal diaphragmatic approach for No.111 lymphadenectomy in patients with Siewert type II esophageal gastric junction adenocarcinoma].

Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
2023

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.

Lancet (London, England)
2023

HER2-low in gastro-oesophageal adenocarcinoma: a real-world pathological perspective.

Journal of clinical pathology
2023

Neoadjuvant Management of Adenocarcinoma of the Esophagus and Esophagogastric Junction: Review of Randomized Evidence and Definition of Optimum Treatment Algorithm.

Oncology
2023

A Nomogram Based on Nutrition-Related Indicators and Computed Tomography Imaging Features for Predicting Preoperative Lymph Node Metastasis in Curatively Resected Esophagogastric Junction Adenocarcinoma.

Annals of surgical oncology
2023

The effectiveness of neoadjuvant chemoradiotherapy in oesophageal adenocarcinoma with presence of extracellular mucin, signet-ring cells, and/or poorly cohesive cells.

The journal of pathology. Clinical research
2023

Patients with esophageal adenocarcinoma showed better prognosis than those with adenocarcinoma of the gastroesophageal junction.

Journal of digestive diseases
2023

Quality-adjusted time without symptoms or toxicity analysis of nivolumab plus chemotherapy versus chemotherapy alone for the management of previously untreated patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma.

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
2023

High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
2023

Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial.

BMC cancer
2023

Phase II clinical trial of sequential treatment with systemic chemotherapy and intraperitoneal paclitaxel for gastric and gastroesophageal junction peritoneal carcinomatosis - STOPGAP trial.

BMC cancer
2023

Global retrospective analysis of clinician- and patient-reported clinical characteristics and humanistic burden of patients with gastroesophageal cancers on first-line treatment.

BMC cancer
2023

Paraconduit hernia after minimally invasive esophagectomy - incidence and risk factors.

Scandinavian journal of gastroenterology
2023

Yield of Repeat Endoscopy for Barrett's Esophagus After Normal Index Endoscopy.

The American journal of gastroenterology
2023

Event-Free Survival as a Surrogate for Overall Survival in Gastric and Gastroesophageal Junction Adenocarcinoma: A Meta-analysis in the Neoadjuvant ± Adjuvant Setting.

Clinical cancer research : an official journal of the American Association for Cancer Research
2023

Immunological effects and activity of multiple doses of zolbetuximab in combination with zoledronic acid and interleukin-2 in a phase 1 study in patients with advanced gastric and gastroesophageal junction cancer.

Journal of cancer research and clinical oncology
2023

Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2023

Acquired microsatellite instability status and loss of HER2 positivity during treatment of gastro-esophageal junction adenocarcinoma.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
2023

Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062.

Japanese journal of clinical oncology
2023

Cytopathological features of gastroesophageal junction adenocarcinoma with enteroblastic differentiation and histopathological correlation.

Cytopathology : official journal of the British Society for Clinical Cytology
2023

Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinoma.

Cancer science
2023

Daily practices in chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma: METESTOMAC French prospective cohort.

Cancer medicine
2022

Phase 1 multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma.

Cell reports. Medicine
2023

Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2022

The optimal neoadjuvant chemotherapy regimen for locally advanced gastric and gastroesophageal junction adenocarcinoma: a systematic review and Bayesian network meta-analysis.

European journal of medical research
2022

Ongoing Controversies in Esophageal Cancer II: Gastrectomy versus Esophagectomy for Siewert Type II Esophageal Adenocarcinoma.

Thoracic surgery clinics
2022

Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study.

The Lancet. Oncology
2023

Perioperative Modified FLOT Versus EOX in Locally Advanced Resectable Gastric and Gastro-Oesophageal Junction Adenocarcinoma: Results of a Matched-Pair Analysis.

Journal of gastrointestinal cancer
2022

Safety and efficacy of preoperative indocyanine green fluorescence marking in laparoscopic gastrectomy for proximal gastric and esophagogastric junction adenocarcinoma (ICG MAP study).

Langenbeck's archives of surgery
2023

Adenocarcinoma of the stomach and esophagogastric junction with low DNA methylation show poor prognoses.

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
2022

Comparison of short-term surgical outcomes between complete mesenteric resection and traditional transhiatal laparoscopic surgery for Siewert type II/III esophagogastric junction adenocarcinoma.

Langenbeck's archives of surgery
2022

Recent advances in multidisciplinary therapy for adenocarcinoma of the esophagus and esophagogastric junction.

World journal of gastroenterology
2022

AI-assisted discovery of an ethnicity-influenced driver of cell transformation in esophageal and gastroesophageal junction adenocarcinomas.

JCI insight

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Adenocarcinoma do esôfago.

É de uma associação que acompanha esta doença? Fale com a gente →

Doença com base genética

Um médico geneticista pode ajudar no diagnóstico de Adenocarcinoma do esôfago e no aconselhamento genético da família.

Vai consultar um especialista? Confirme o registro dele no conselho.
Conselhos e sociedades

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Perguntas frequentes

O que as famílias mais perguntam sobre esta doença — cada resposta com a fonte de onde saiu

Respostas geradas por IA a partir das fontes citadas

Trata-se de um tumor maligno de células glandulares localizado principalmente no terço inferior do esôfago. Ele costuma desenvolver-se a partir de lesões prévias na mucosa, sobretudo associadas ao esôfago de Barrett.

Referências

Fontes citadas no texto, publicações do grafo e bases de dados usadas neste verbete

7 publicações do grafo RarasNet (PubMed) · 5 bases de dados. Títulos, periódicos e PMIDs vêm direto da fonte, sem intermediação de IA.

  1. ORPHA:99976
    Orphanet
  2. Q18556542
    Wikidata

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Citar este verbete

Raras. (s.d.). Adenocarcinoma do esôfago. Em Raras — Enciclopédia de Doenças Raras do Brasil. https://raras.org/doenca/adenocarcinoma-do-esofago

Formato APA. Conteúdo sob CC BY 4.0 — reuso livre com atribuição.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Compêndio · Raras BR

Adenocarcinoma do esôfago

ORPHA:99976 · MONDO:0005028
Prevalência
1-9 / 100 000
Herança
Not applicable
CID-10
C15.2 · Neoplasia maligna da porção abdominal do esôfago (esôfago abdominal)
CID-11
Ensaios
107 ativos
Início
Adult, Elderly
Prevalência
0.0 (Europe)
GARD
GARD:16927
MedGen
UMLS
C0279628
EuropePMC
Wikidata

📋 Origem dos dados

Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.

Doença rara (ontologia)
fonte: Orphanet
Identificador unificado
fonte: MONDO
NIH/GARD
fonte: GARD (NIH)
Indexação biomédica
fonte: MeSH (NLM)
Dado público estruturado
fonte: Wikidata
Medicamentos aprovados FDA
fonte: FDA OpenFDA
Rara